Health Economics›Acute myeloid leukemia pediatric›Upfront induction therapy

Upfront induction therapy

Acute myeloid leukemia pediatric · 19 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
COG AAML0531 arm B (Gemtuzumab) N/A - intrathecal component	—	R 328 792	28d	—	—	—	—	1
COG AAML1031 arm A (high-risk) N/A - intrathecal component	—	R 148 737	28d	—	—	—	—	—
COG AAML1031 arm C (FLT3/ITD+) N/A - intrathecal component	—	R 144 454	36d	—	—	—	—	—
COG AAML1031 arm A (low-risk) N/A - intrathecal component	—	R 107 186	10d	—	—	—	—	—
ADE and GO Variant #01	—	R 53 387	10d	—	—	—	—	1
DA 3+10, GO Variant #01	—	R 51 644	10d	—	—	—	—	1
FLAG-Ida Variant #01	—	R 35 219	28d	—	~5.4 mo	—	—	3
ADE (high-dose Ara-C) Variant #01	—	R 24 287	6d	—	—	—	—	1
D-ZAPO Variant #01	—	R 20 324	14d	—	—	—	—	—
DAT Variant #03	—	R 20 185	9d	—	—	—	—	—
AIE Variant #01	—	R 19 409	7d	—	—	—	—	—
MEC Variant #01	—	R 19 351	28d	—	~5.5 mo	—	—	4
DA 3+10 Variant #01	—	R 12 698	10d	—	—	—	—	2
DCTER Variant #01	—	R 12 697	4d	—	—	—	—	—
ADE (standard-dose Ara-C) Variant #07	—	R 11 856	10d	—	—	—	—	2
7+3d Variant #01	—	R 6 129	—	—	~15.1 mo	—	—	11
Mercaptopurine monotherapy Variant #01	—	R 4 912	—	—	—	—	—	—
Cytarabine, Doxorubicin, Vincristine, Prednisolone Variant #01	—	R 2 976	—	—	—	—	—	—
PATCO Variant #01	—	R 2 209	14d	—	—	—	—	—

19 of 19 regimens shown